2245848-05-7
2245848-05-7
Chemical Structure
Murizatoclax
Synonym(s): AMG 397
- CAS No.: 2245848-05-7
- Formula:C42H57ClN4O5S
- Molecular Weight:765.44
InChIKey: BJTFTQIBRVBSBH-VCQPVEJUSA-N
SMILES: O=C(C(C=C1)=CC2=C1OC[C@]3(CCCC4=C3C=CC(Cl)=C4)CN2C[C@@]5([H])[C@](CC5)([H])[C@](CN6C[C@](CCCC7)([H])N7CC6)(OC)/C=C/C[C@H](C)[C@H]8C)NS8(=O)=O
Biological Activity: Murizatoclax (AMG 397) is a potent, selective and orally active inhibitor of myeloid leukemia 1 (MCL-1) inhibitor, with a Ki of 15 pM. Murizatoclax competitive binds to the BH3-binding groove of MCL1 with pro-apoptotic BCL-2 family members. Murizatoclax can be used for the research of cancer[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Murizatoclax | 98.47% | Murizatoclax (AMG 397) is a potent, selective and orally active inhibitor of myeloid leukemia 1 (MCL-1) inhibitor, with a Ki of 15 pM. Murizatoclax competitive binds to the BH3-binding groove of MCL1 with pro-apoptotic BCL-2 family members. Murizatoclax can be used for the research of cancer. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Murizatoclax (Standard) | ≥98% | Murizatoclax (Standard) is the analytical standard of Murizatoclax (HY-109184). This product is intended for research and analytical applications. Murizatoclax (AMG 397) is a potent, selective and orally active inhibitor of myeloid leukemia 1 (MCL-1) inhibitor, with a Ki of 15 pM. Murizatoclax competitive binds to the BH3-binding groove of MCL1 with pro-apoptotic BCL-2 family members. Murizatoclax can be used for the research of cancer. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Wang H, et, al. Targeting MCL-1 in cancer: current status and perspectives. J Hematol Oncol. 2021 Apr 21;14(1):67. [Content Brief]
- [2]. Caenepeel S, et al. Abstract 6218: discovery and preclinical evaluation of AMG 397, a potent, selective and orally bioavailable MCL1 inhibitor. Cancer Res. 2020;80(16 Supplement):6218.
